Last updated: September 7, 2026
PRALUENT, the PCSK9 inhibitor alirocumab, has developed into a durable but smaller cardiovascular franchise than initially projected. Sanofi and Regeneron launched the drug in 2015 against Amgen’s REPATHA, but high launch pricing, payer restrictions, competing PCSK9 therapy, and later competition from inclisiran constrained uptake. The franchise remains commercially relevant because of persistent demand for LDL-cholesterol reduction, but its growth profile is mature and its long-term value depends on access, dosing economics, and protection from biosimilar competition.
What is PRALUENT and who markets alirocumab?
PRALUENT is a fully human monoclonal antibody that binds PCSK9 and increases hepatic clearance of low-density lipoprotein cholesterol. It is administered by subcutaneous injection, primarily at 75 mg or 150 mg every two weeks, with a 300 mg monthly option in the United States.
| Attribute |
PRALUENT |
| Active ingredient |
Alirocumab |
| Drug class |
PCSK9 monoclonal antibody |
| Originators |
Regeneron and Sanofi |
| U.S. approval |
July 24, 2015 |
| U.S. regulatory pathway |
Biologics license application under Section 351(a) |
| Primary use |
LDL-cholesterol reduction in hypercholesterolemia and cardiovascular-risk reduction |
| U.S. manufacturer and license holder |
Regeneron Pharmaceuticals |
| Global commercial partner |
Sanofi |
| Main competitor |
REPATHA, evolocumab |
| Alternative therapy |
LEQVIO, inclisiran |
| Product type |
Reference biologic, not a conventional small-molecule generic product |
The FDA initially approved PRALUENT for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional LDL reduction. The label was later expanded to include reduction of cardiovascular-event risk in adults with established cardiovascular disease.[1]
How has PRALUENT’s financial trajectory developed?
PRALUENT’s sales trajectory has been shaped by price reductions, formulary access, and competition rather than by a lack of clinical demand.
The product launched in the United States at an annual list price of approximately $14,600. Sanofi and Regeneron reduced the annual list price to $5,850 in 2018 after payer pressure and slow uptake. That reduction improved access but compressed revenue per treated patient.[2]
Sanofi reports PRALUENT sales in euros in its annual filings, while Regeneron reports collaboration economics and product-related revenue under its own accounting arrangements. The two companies’ reported figures are therefore not directly additive. Public filings show a franchise that moved from launch-stage expansion to mature, price-sensitive sales.
| Period |
Financial development |
| 2015-2016 |
Launch phase, with access barriers and rapid competitive response from REPATHA |
| 2017-2018 |
Sales growth remained below initial expectations; price reduction implemented in 2018 |
| 2019-2021 |
Lower pricing and improved reimbursement supported volume, while the COVID-19 period affected cardiovascular diagnosis and treatment initiation |
| 2022-2024 |
Mature brand profile, continued demand from high-risk patients, and pressure from REPATHA and LEQVIO |
| Long term |
Revenue depends on branded persistence, payer coverage, indication expansion, and timing of biosimilar entry |
The commercial pattern is typical for a specialty biologic with high clinical utility but restrictive utilization management. PRALUENT is generally prescribed after statins, ezetimibe, or both fail to produce adequate LDL reduction or are not tolerated. This step-therapy sequence limits the addressable treated population even though the underlying cardiovascular-risk population is large.
What drove PRALUENT’s revenue performance?
High launch pricing limited early adoption
The original price positioned PRALUENT as a high-value cardiovascular biologic but created resistance from commercial payers and pharmacy-benefit managers. Payers frequently required prior authorization and documented failure of statin therapy and other lipid-lowering agents.
The 2018 price reduction narrowed the price gap with REPATHA and increased the likelihood of preferred formulary placement. The tradeoff was lower revenue per prescription and a greater need for patient volume.
REPATHA established strong competitive pressure
REPATHA, marketed by Amgen, entered the same PCSK9 category in 2015. The products have similar mechanisms, overlapping approved uses, and comparable administration requirements. Competitive contracting became a major determinant of access.
REPATHA gained commercial momentum through broader contracting, cardiovascular-outcomes positioning, and Amgen’s scale in the cardiovascular market. PRALUENT remained clinically competitive, but it did not achieve the category leadership that the launch forecasts had anticipated.
Cardiovascular outcomes data supported medical use
The ODYSSEY OUTCOMES trial showed that alirocumab reduced major adverse cardiovascular events in patients with recent acute coronary syndrome and elevated residual risk despite intensive statin therapy.[3] The data supported the 2019 FDA label expansion and gave PRALUENT a basis for use beyond LDL-number reduction.
The commercial benefit was moderated by treatment guidelines, prior authorization requirements, and the need to identify patients with sufficiently high residual risk.
LEQVIO changed the competitive discussion
Novartis’ LEQVIO, or inclisiran, uses small-interfering RNA technology to inhibit PCSK9 production. It is administered initially, again at three months, and then every six months. That dosing schedule creates a potential adherence advantage over self-administered PCSK9 antibodies.
LEQVIO’s commercial model differs from PRALUENT’s because administration by a health-care professional may support medical-benefit reimbursement rather than pharmacy-benefit reimbursement in some settings. Its uptake has been gradual, but it creates a longer-term competitive risk for injectable PCSK9 antibodies.
What is the FDA regulatory status of PRALUENT?
PRALUENT is FDA-approved for LDL reduction in specified high-risk patients and for cardiovascular-event risk reduction in adults with established cardiovascular disease. The product is also approved in other major markets, including the European Union, subject to local labeling and reimbursement decisions.
The principal regulatory milestones were:
| Date |
Event |
| July 24, 2015 |
FDA approval of PRALUENT |
| 2015 |
European approval for hypercholesterolemia indications |
| 2018 |
U.S. annual list price reduced to $5,850 |
| 2019 |
FDA label expanded to include cardiovascular-event risk reduction after ODYSSEY OUTCOMES |
| 2020 onward |
Continued commercial use under more restrictive, value-based access conditions |
PRALUENT is a biologic reference product. Potential follow-on competition would proceed through the biosimilar pathway under Section 351(k), not through the ordinary abbreviated new drug application pathway used for small-molecule generics.
What patents protect PRALUENT?
PRALUENT’s protection includes antibody-related composition claims, target-binding claims, therapeutic-use claims, and manufacturing or formulation positions. The exact enforceability of each patent depends on claim scope, prosecution history, validity, and jurisdiction.
The most important U.S. patent risk event involved Amgen’s PCSK9 patent estate rather than a successful loss of PRALUENT’s commercial rights. In Amgen v. Sanofi, the U.S. Supreme Court held in 2023 that Amgen’s broad genus claims covering antibodies that bind PCSK9 and block LDL-receptor degradation were not enabled across their full scope.[4] The ruling reduced the risk that PRALUENT would be excluded from the U.S. market based on those Amgen patents.
| Patent issue |
Commercial relevance |
| Composition-of-matter claims |
Protect alirocumab molecules and defined antibody structures |
| Binding and functional claims |
Cover interaction with PCSK9 or inhibition of PCSK9 activity |
| Method-of-use claims |
Cover LDL reduction and cardiovascular-risk reduction |
| Formulation claims |
May protect concentrations, excipients, stability, or delivery characteristics |
| Manufacturing claims |
Can increase technical barriers to biosimilar development |
| Amgen PCSK9 patents |
Litigation threat was materially weakened after the 2023 Supreme Court decision |
Public patent databases and regulatory records should be analyzed patent by patent before a launch decision. A single “expiration date” does not capture the full risk profile because different patents can expire at different times and may have patent-term adjustment, terminal disclaimers, pediatric extensions, or jurisdiction-specific status.
When does PRALUENT lose exclusivity?
PRALUENT received 12 years of reference-biologic exclusivity under the Biologics Price Competition and Innovation Act, beginning on the date of first licensure in the United States. On that statutory framework, the core data-exclusivity period runs to July 24, 2027.[5]
This date does not mean that an automatic biosimilar launch could occur on July 25, 2027. A biosimilar applicant must complete the FDA review process, satisfy the applicable patent-notice framework, and address any unexpired, enforceable patents. Patent litigation can delay launch even after statutory biologic exclusivity ends.
| Exclusivity barrier |
Approximate status |
| FDA reference-product exclusivity |
Runs through July 24, 2027 |
| Patent protection |
Multiple claims and families may extend beyond data exclusivity |
| Biosimilar approval |
Possible after statutory exclusivity, subject to FDA review |
| Commercial launch |
Depends on patent resolution, settlement terms, and litigation |
| Small-molecule generic substitution |
Not applicable |
Is PRALUENT listed in the Orange Book?
PRALUENT is a biologic and is principally tracked through the FDA’s Purple Book framework rather than the traditional Orange Book system for small-molecule drugs. The Orange Book is therefore not the primary source for PRALUENT’s biologic-exclusivity analysis.
The relevant questions are whether PRALUENT is listed as a reference product in the Purple Book, when its 12-year exclusivity period ends, and which patents can be asserted against a biosimilar applicant. A conventional Orange Book Paragraph IV filing is not the standard route for challenging PRALUENT.
Are there Paragraph IV challenges to PRALUENT?
A conventional Paragraph IV abbreviated new drug application challenge is not the expected pathway because PRALUENT is a biologic. Biosimilar applicants instead use the Section 351(k) framework and the patent-exchange procedures established by the BPCIA.
The commercial equivalent of a Paragraph IV risk is a biosimilar applicant’s assertion that relevant patents are invalid, unenforceable, or not infringed. The resulting dispute can lead to federal patent litigation, negotiated launch dates, or a license permitting an earlier biosimilar entry.
No broad, established U.S. generic-entry wave for PRALUENT had emerged through the latest publicly available regulatory and company disclosures used for this analysis.
How strong is the PRALUENT patent estate?
The estate is commercially meaningful but less predictable than a single, clearly dominant composition-of-matter patent. Its strength depends on:
- The remaining life of core antibody claims.
- The scope of formulation and concentration claims.
- The validity of functional PCSK9-binding claims.
- The ability to prove infringement against a biosimilar antibody.
- The geographic coverage outside the United States.
- The commercial value of obtaining an injunction or negotiated launch delay.
The Supreme Court’s Amgen decision improved the competitive position of alirocumab by invalidating broad antibody genus claims that lacked sufficient enablement. It also illustrates the vulnerability of broad functional antibody claims in the PCSK9 field.
What generic and biosimilar launch risks exist?
The most likely first-entry risk is a biosimilar rather than a traditional generic. Development barriers include:
- Demonstrating analytical similarity to a complex monoclonal antibody.
- Establishing pharmacokinetic and pharmacodynamic similarity.
- Addressing immunogenicity.
- Reproducing formulation and device performance.
- Navigating patent litigation.
- Securing payer coverage against entrenched branded and competing products.
- Achieving economic scale in a price-pressured cardiovascular market.
A biosimilar entrant would face a category with established products, lower net pricing than at launch, and substantial payer bargaining power. Entry could still be attractive because PCSK9 therapy addresses a large population of patients with inadequately controlled LDL cholesterol.
Which companies challenge PRALUENT commercially?
| Company |
Product |
Competitive issue |
| Amgen |
REPATHA, evolocumab |
Direct PCSK9-antibody competitor with established market presence |
| Novartis |
LEQVIO, inclisiran |
Longer dosing interval and alternative reimbursement model |
| Generic manufacturers |
Potential alirocumab biosimilars |
Price competition after regulatory and patent barriers fall |
| Sanofi and Regeneron |
PRALUENT |
Defend share through access, evidence, contracting, and lifecycle management |
The main commercial contest is not only between molecules. It also involves distribution channel, dosing frequency, payer preference, injection devices, adherence, and whether the product is billed through pharmacy or medical benefits.
What licensing and settlement agreements affect PRALUENT?
PRALUENT originated from the Regeneron-Sanofi collaboration. The companies divided development, commercialization, and economic responsibilities under a strategic alliance covering alirocumab and other collaboration activities.
The most consequential legal resolution was the outcome of Amgen’s litigation over PCSK9 antibodies. The Supreme Court’s 2023 decision removed the primary exclusion risk created by Amgen’s enablement claims.[4] No widely reported biosimilar settlement had established a definitive U.S. launch date for a competing alirocumab product in the public record available through 2024.
How does PRALUENT compare with REPATHA and LEQVIO?
| Factor |
PRALUENT |
REPATHA |
LEQVIO |
| Active ingredient |
Alirocumab |
Evolocumab |
Inclisiran |
| Technology |
Monoclonal antibody |
Monoclonal antibody |
Small-interfering RNA |
| Target |
PCSK9 |
PCSK9 |
PCSK9 production |
| Dosing |
Every two weeks or monthly |
Every two weeks or monthly, depending on presentation |
Initial dose, three months, then every six months |
| Outcomes evidence |
ODYSSEY OUTCOMES |
FOURIER |
Cardiovascular-outcomes evidence developed separately from LDL-lowering approval |
| Main commercial strength |
Established label and broad experience |
Scale and competitive positioning |
Dosing convenience and medical-benefit potential |
| Main weakness |
Payer controls and mature category |
Same-class competition |
Slower adoption and administration logistics |
PRALUENT’s durable value is strongest in patients who require substantial LDL reduction, have established cardiovascular disease, and receive favorable formulary access. Its weaker position is in price-sensitive formularies where REPATHA has stronger contracting or where LEQVIO’s dosing model changes treatment economics.
What is the revenue exposure and investment outlook?
PRALUENT is unlikely to return to its original launch-price economics. The key financial variables are treated-patient growth, net price, payer access, adherence, and biosimilar timing.
For Sanofi, PRALUENT is a mature specialty-care product within a much larger pharmaceutical portfolio. For Regeneron, it remains part of a collaboration-based revenue stream but is smaller than the company’s leading immunology and ophthalmology products. The franchise can generate recurring cash flow, but it is not the primary growth engine for either company.
The main downside risks are:
- Further net-price erosion.
- Loss of preferred formulary status.
- Increased LEQVIO adoption.
- Biosimilar entry after 2027.
- Patent invalidity or non-infringement findings.
- Declining use of injectable therapies as newer lipid-lowering approaches expand.
The main upside factors are:
- Greater diagnosis of familial hypercholesterolemia.
- More aggressive secondary prevention after cardiovascular events.
- Improved reimbursement.
- Evidence supporting use in statin-intolerant patients.
- Successful patient-support programs.
- Delayed biosimilar entry caused by patent litigation or regulatory complexity.
Key Takeaways
- PRALUENT is alirocumab, a PCSK9 monoclonal antibody marketed by Sanofi and Regeneron.
- The drug launched in 2015 at approximately $14,600 annually and later moved to a $5,850 U.S. list price.
- Its financial trajectory reflects volume growth offset by price compression and payer controls.
- REPATHA is the principal direct competitor; LEQVIO is the main longer-acting alternative.
- PRALUENT received 12 years of U.S. reference-biologic exclusivity from July 24, 2015, through July 24, 2027.
- Biosimilar competition, not a conventional Paragraph IV generic, is the relevant post-exclusivity risk.
- The 2023 Supreme Court decision in Amgen v. Sanofi reduced the risk from Amgen’s broad PCSK9 antibody claims.
- A definitive U.S. biosimilar launch date had not been established in the public record through 2024.
- The franchise remains commercially durable but is unlikely to regain launch-era pricing power.
FAQs
Can a generic version of PRALUENT be substituted automatically?
No. PRALUENT is a biologic, so competition would generally come through a biosimilar approved under Section 351(k), not an automatically substitutable small-molecule generic.
Does PRALUENT have cardiovascular-outcomes approval?
Yes. The FDA expanded the label in 2019 to include reduction of cardiovascular-event risk in adults with established cardiovascular disease, based primarily on ODYSSEY OUTCOMES data.
Is PRALUENT protected by the Amgen PCSK9 patents?
The Supreme Court’s 2023 decision rejected the enablement of Amgen’s broad antibody genus claims. That ruling removed a major exclusion threat to PRALUENT in the United States.
What is the largest commercial threat to PRALUENT?
The largest immediate threat is sustained competition from REPATHA and the resulting payer pressure. Over time, LEQVIO and biosimilar alirocumab products create additional risk.
What determines PRALUENT’s post-2027 value?
Post-2027 value will depend on remaining patent claims, biosimilar timing, net pricing, formulary access, cardiovascular-outcomes demand, and the ability of Sanofi and Regeneron to retain high-risk patients.
References
-
U.S. Food and Drug Administration. (2015). FDA approves Praluent to treat certain patients with high cholesterol. FDA.
-
Sanofi. (2018). Sanofi announces new price for Praluent in the United States. Sanofi press release.
-
Schwartz, G. G., Steg, P. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Kim, Y. U., Mahaffey, K. W., Martinez, F., Rorick, T., White, H. D., Zeiher, A. M., & ODYSSEY OUTCOMES Committees and Investigators. (2018). Alirocumab and cardiovascular outcomes after acute coronary syndrome. New England Journal of Medicine, 379(22), 2097-2107.
-
Supreme Court of the United States. (2023). Amgen Inc. v. Sanofi, 598 U.S. 594. U.S. Reports.
-
Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §7002, 124 Stat. 119, 804-821.
